Dataset Information


Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily.

ABSTRACT: Dasatinib is considered an effective drug in imatinib-resistant chronic myeloid leukemia. Although reported to be well-tolerated, severe events such as pleural or pericardial effusion have been reported at 140 mg daily. We examined our chronic myeloid leukemia patients treated with dasatinib at 100 mg or 50 mg daily and identified 4 of 13 patients who developed marked effusion formation. In 2 patients, grade III/IV pleural and/or pericardial effusions were recorded. All 4 patients had received previous anti-leukemia therapy but none had pre-existing cardiac or pulmonary diseases. In 3 patients, dasatinib had to be discontinued despite treatment with diuretics and glucocorticosteroids. In conclusion, dasatinib-treated chronic myeloid leukemia patients are at risk for the development of pleural and pericardial effusions even when the drug is administered at 100 mg or 50 mg daily. Therefore, all patients should be examined for pre-existing comorbidity and risk factors before starting dasatinib and all should have repeated chest X-rays during long-term dasatinib therapy.


PROVIDER: S-EPMC3012781 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2019-01-01 | S-EPMC6312029 | BioStudies
2018-01-01 | S-EPMC6388399 | BioStudies
1000-01-01 | S-EPMC3684141 | BioStudies
2018-01-01 | S-EPMC5929218 | BioStudies
2016-01-01 | S-EPMC5118045 | BioStudies
2010-01-01 | S-EPMC4081177 | BioStudies
2011-01-01 | S-EPMC3068059 | BioStudies
2021-01-01 | S-EPMC7918666 | BioStudies
2020-01-01 | S-EPMC7501910 | BioStudies
2014-01-01 | S-EPMC3962969 | BioStudies